Clinical Trial

Investigating the Impact of the Seaweed Derived Food Additive, Carrageenan, on the Human Gut Microbiome

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2024 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to investigate whether a seaweed derived food additive, carrageenan, has an impact on the human gut microbiome in vivo. The primary purpose is to assess whether consumption of a carrageenan containing product for 4 weeks can alter the bacterial composition of the gut microbiome in healthy individuals and whether the addition of a prebiotic fibre, inulin, to the product has an enhanced beneficial impact of the gut composition. The main questions to answer are: Does the consumption of a confectionary item containing carrageenan and inulin lead to a positive impact on the faecal microbial community when compared to the confectionary item containing no carrageenan and no inulin (placebo)? Participants will be asked to consume 2 gummy sweets for 4 week period and provide stool and urine samples on 3 occasions over a 9 week period. Does the consumption of a confectionary item containing carrageenan and inulin improve gastrointestinal comfort measured using overall SHS-GI score when compared to baseline measurements recorded during run in period?
Trial Details
NCT Number NCT06738329
Lead Sponsor University of Reading
Collaborators: Cargill R&D Centre Europe, Havenstraat 84, 1800 Vilvoorde, Belgium
Conditions Gut Microbiome, Healthy Donors
Enrollment 99 participants
Start Date 2024-10-01
Primary Completion 2025-05-30 (estimated)
Study Completion 2025-05-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-17